Sanofi has formally asked the FDA to remove its type 1 diabetes drug from the fast-track review program. This decision appears to be influenced by recent actions taken by a political appointee.
The request comes in light of scrutiny surrounding Commissioner Marty Makary's new review process, which has faced criticism for its handling of drug evaluations.
This development raises questions about the impact of political factors on the regulatory process for critical medications.